Seres stock

What are Seres Therapeutics' stock price targets for the next year? Seven brokers have set annual target prices for Seres Therapeutics stock. Their predictions range from $ to $. On average, they expect the Seres Therapeutics stock to rise to $1 over the next 12 months.

Who underwrote Seres Therapeutics' IPO?

Goldman Sachs and BofA Merrill ■■■■■ acted as underwriters in the IPO, while Leerink Partners and Canaccord Genuity acted as co-directors. What is Seres Therapeutics' ticker symbol?

Does Seres Therapeutics' SER-109 work for C diff?

CAMBRIDGE, MA, September 15, 2021 Seres Therapeutics, Inc. (Nasdaq: MCRB), a leader in microbiome therapy, today announced that 300 subjects have been recruited into the open-label ECOSPOR IV study to evaluate SER109, an ■■■■ microbiome experiment to treat recurrent C. difficile infection (rCDI ).

What is seresther Therapeutics' mailing address?

The mailing address for Seres Therapeutics is 200 SIDNEY STREET 4TH FLOOR, CAMBRIDGE MA, 02139. The biotech company can be reached at (617) 9459626 or by email at ctanzi@.

Location

What is the upside for Seres Therapeutics' stock?

Their forecasts range between $ and $, on average they expect Seres Therapeutics stock to rise as much as $ in the next 12 months. This indicates a possible increase in the current value of the shares. View the price targets of Seres Therapeutics analysts or view the top-rated Wall Street analysts.

Is Seres Therapeutics (MCRB) stock a good buy?

Based on 7 analyst ratings over the past year, the consensus forecast for Seres Therapeutics Buy is based on current ratings of 1 Sell, Hold 1, and Buy 5 for MCRB. Average annual target price for Seres Therapeutics is $ with $ high target and $ low target.

How does Seres Therapeutics's earnings compare to analysts' estimates?

The biotech company reported sales of millions for the quarter, compared to analyst estimates in the millions. Seres Therapeutics posted negative net profit margins and a negative return on equity compared to the prior year based on Seres Therapeutics' earnings history.

How has covid-19 affected seseres Therapeutics' stock?

Seres Therapeutics traded at $11, on March 11, 2020, when COVID19 (coronavirus) reached pandemic status, according to the World Health Organization. Since then, MCRB shares have risen and are now trading at USD. See which stocks have been most affected by COVID19.

Where did yoga originate

How much does Seres Therapeutics make a year?

Seres Therapeutics has a market cap of millions of US dollars and profits of millions per year. The biotech company has net income (earnings) or ($) of $89,130 ​​based on earnings per share for each year. How many employees does Seres Therapeutics have? Seres Therapeutics employs 155 people worldwide.

Who underwrote seres therapeutics' ipo 2020

CAMBRIDGE, MA (BUSINESS WIRE) October 10, 2020 Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the first positive results from the ECOSPOR III phase 3 pivotal study of experimental ■■■■ microbiome treatment SER109 for relapsed C. difficile (ICD).

Who is the chief commercial and Strategy Officer of Seres?

In June 2020, Ceres appointed Terry Young as Chief Strategy and Trading Officer. The company has organized events to support the success of potential future commercialization.

What does the SER-109 Phase 3 data mean for Seres?

- Positive data from Phase 3 of SER109 confirms the validation of the Seres microbiome therapy platform and the further development of its line of product candidates -.

Vault

What is SER-109 breakthrough therapy?

The FDA has granted SER109 Advanced Therapy status and an orphan drug for CDI. SER109 is fundamentally different from a ■■■■■ microbiota transplant (FMT).

Does SER-109 work for C diff?

Ceres announced the first positive results from the SER109 phase 3 ECOSPOR III trial for the treatment of relapses in C. difficile. Ceres is currently recruiting subjects for the open-label SERES013 ECOSPOR IV trial for SER109. All eligible participants and study participants will receive the active study drug SER109.

What is SER-109 and how does it work?

SER109 is designed to break the cycle of repeated C. diff infections by targeting multiple disease-related pathways simultaneously to address key aspects of the disease. SER109 is an experimental microbiome-based ■■■■ biologic therapy designed to prevent recurrence of C. diff infection.

Can microbiome drug serser-109 reduce recurrence of RCDI?

SER109, an investigational drug from a purified trace microbiome, reduced recurrences in an open-dose phase (Ph)1 study in patients with multiple rCDIs.

Is serser-287 approved by the FDA?

SER287 has received FDA approval for accelerated use and irresponsible handling.

Does seres therapeutics' ser-109 work for c diff in cancer

SER109 is an experimental bio-based ■■■■ therapy to reduce recurrence of C. difficile infection (CDI), enabling patients to achieve long-lasting clinical responses, break the cycle of CDI recurrence, and restore the diversity of the gastrointestinal microbiome.

What is serser-109 and how does it work?

SER109 is composed of bacteria designed to modulate the following gut microbiome functions to treat C. difficile infection: Recruitment: A Phase 1b study in Australia and New Zealand in patients with mild to moderate ulcerative colitis.

Is SER-109 an FDA approved drug?

The FDA has designated SER109 with "Breakthrough Therapy" and "Orphan Drug" status. In a Phase 3 clinical trial, SER109 achieved high sustained clinical response rates in patients with relapsed CDI with a favorable safety profile comparable to placebo.

Gossip girl blair and serena

What is the SER-109 open label study label study?

The open-label study of SER109 in patients with relapsed CDI, including the first relapse, is ongoing. The open study aims to expand the safety database SER109 to support an application for biological product approval (BLA) with the FDA.

Does seres therapeutics' ser-109 work for c diff treatment

Seres (NASDAQ: MCRB) announced Monday that his drug SER109 is superior to placebo in treating Clostridioides difficile (C. diff) infection. The Cambridge, Massachusetts-based biotech company said the results far exceed FDA regulatory parameters. The next step is to request an interview to discuss the specific requirements for such a presentation.

How effective is SER-109 for C diff?

In a pivotal Phase 3 clinical study, patients treated with SER109 had a lower relapse rate than patients treated with antibiotics. The results showed that SER109 significantly reduced the risk of C. diff recurrence.

Is there a clinical trial for SER-287?

Seres completed enrollment in the ECORESET Phase 2b trial to evaluate the safety and efficacy of SER287 in patients with mild to moderately active ulcerative colitis. Read more about their ongoing clinical trials.

Does seres therapeutics' ser-109 work for c diff products

Product Overview SER109 is a world-class investigational microbial drug administered ■■■■■■ after antibiotics to reduce the recurrence of C. difficile infection (CDI) in patients with recurrent CDI.

What are the results of the SER-109 study?

Seres Therapeutics Announces First Positive Phase 3 Study ECOSPOR III SER109 Results in Recurrent C.

Does seres therapeutics' ser-109 work for c diff in children

Seres Therapeutics has developed an ■■■■ drug called SER109 that aims to prevent the return of Cdiff by rebuilding the microbiome. This Ecobiotic drug is being investigated in a large Phase 3 clinical trial recruiting patients with multiple C-diff infections.

Lot